Physician profile
Lee Hicks
NPI 1356342125
$4,821.84
in general payments reported to CMS, 2019-2025
49 companies · $797 in 2025
The $797 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,012 · 2020: $437 · 2021: $256 · 2022: $268 · 2023: $396 · 2024: $655 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,821 · Education: $27.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,820.71 |
| Education | $27.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $487.46 | 2019-2023 | Lumakras |
| Janssen Biotech, INC. | $381.74 | 2019-2025 | Imbruvica, Carvykti, Tecvayli |
| Novartis Pharmaceuticals Corporation | $342.56 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $265.39 | 2019-2025 | Tagrisso, Enhertu |
| Merck Sharp & Dohme LLC | $253.86 | 2019-2025 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $208.37 | 2019-2025 | Opdualag |
| Pfizer INC. | $192.26 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $180.68 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $172.19 | 2022-2025 | Onivyde |
| Alexion Pharmaceuticals, INC. | $168.80 | 2019-2025 | Ultomiris |
| Incyte Corporation | $154.78 | 2019-2025 | Jakafi |
| Sirtex Medical INC | $153.50 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $151.10 | 2019-2025 | Libtayo |
| Daiichi Sankyo INC. | $133.98 | 2019-2024 | Injectafer |
| Genentech USA, INC. | $124.71 | 2019-2025 | Venclexta, Tecentriq |
Show all 47 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Hicks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.